Fampyra
E28893
Fampyra is a prescription medication (prolonged-release fampridine) used to improve walking in adults with multiple sclerosis.
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
brand name drug
→
medicinal product → |
| actsOn | central nervous system → |
| approvalYear | 2011 → |
| approvedBy | European Medicines Agency → |
| commonAdverseEffect |
dizziness
→
headache → insomnia → nausea → urinary tract infection → |
| containsExcipient | lactose → |
| contraindicatedIn |
history of seizures
→
moderate or severe renal impairment → |
| developedBy |
Biogen
→
surface form: "Biogen Idec"
|
| dosingInterval | every 12 hours → |
| hasActiveIngredient |
4-aminopyridine
→
fampridine → |
| hasApprovalRegion | European Union → |
| hasATCCode | N07XX07 → |
| hasDosageForm | prolonged-release tablet → |
| hasInternationalNonproprietaryName | fampridine → |
| hasRouteOfAdministration | oral → |
| hasStrength | 10 mg prolonged-release tablet → |
| hasTradeName | Fampyra → |
| improvementAssessmentTool | Timed 25-Foot Walk test → |
| improves |
walking ability in multiple sclerosis patients
→
walking speed in multiple sclerosis patients → |
| indicatedFor |
impaired walking in multiple sclerosis
→
multiple sclerosis → |
| intendedPopulation | adults → |
| isExtendedReleaseFormulationOf | fampridine → |
| legalStatusEU | prescription only medicine → |
| marketingAuthorisationHolder |
Biogen
→
surface form: "Biogen Netherlands B.V."
|
| mechanismOfAction |
blocks voltage-gated potassium channels
→
enhances conduction in demyelinated axons → |
| notIndicatedFor | patients under 18 years of age → |
| pharmacologicalClass | potassium channel blocker → |
| pregnancyCategory | use only if potential benefit justifies potential risk → |
| requires | prescription → |
| requiresMonitoring |
renal function
→
seizure risk → |
| riskManagementPlanRequiredBy | European Medicines Agency → |
| seriousAdverseEffect | seizure → |
| storageCondition | store below 25°C → |
| therapeuticArea | neurology → |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.